Recruiting

Observational Study

Sponsor:

Mayo Clinic

Code:

NCT03478826

Conditions

Interstitial Lung Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

ILD

Healthy

Pneumonia

Study Details

Brief summary:

To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.

Conditions

Interstitial Lung Disease

Study ID

NCT03478826

Start date

Aug 1, 2018

Status verified date

Apr, 2026

Completion date

Jan, 2028

Anticipated

Primary completion date

Jan, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia
  • Patients willing to provide written informed consent

Exclusion Criteria:

  • Unwillingness/unable to give blood samples

Study Design

Enrollment

635 participants

Anticipated

Interventions and Outcome Measures

Arms

ILD

250 patients (male and females >18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.

Healthy

100 healthy participants as a control group.

Pneumonia

25 patients with pneumonia as a control group.

Interventions

ILD

100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis

Healthy

100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.

Pneumonia

100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.

Primary outcome measure

  • Future Disease Management [ Time Frame: 1 visit ]

Central Contacts and Locations

Central contacts

Michael Stachowitz

507-284-4862Stachowitz.Michael@mayo.edu

Locations

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Michael Stachowitz

507-284-4862Stachowitz.Michael@mayo.edu

Principal Investigator:

Eva Carmona, M.D., Ph.D.

More Information

Sponsor

Mayo Clinic

Last update posted

Apr 29, 2026

Last verified

Apr, 2026

Keywords

  • ILD

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-04-29.